Skip to main content
Erschienen in: International Urogynecology Journal 12/2011

01.12.2011 | Original Article

Determining outcomes, adverse events, and predictors of success after sacral neuromodulation for lower urinary disorders in women

verfasst von: Tajnoos Yazdany, Narender Bhatia, John Nguyen

Erschienen in: International Urogynecology Journal | Ausgabe 12/2011

Einloggen, um Zugang zu erhalten

Abstract

Introduction and hypothesis

The objective of this study was to determine the predictors of successful treatment of lower urinary tract disorders with sacral nerve stimulation (SNS) and the rate of adverse events and reoperations.

Methods

A retrospective case series of patients who underwent SNS at a single institution was analyzed.

Results

Seventy-six patients underwent stage I trial of SNS. Fifty-eight (76%) patients experienced improvement and underwent placement of an implantable pulse generator with a mean follow-up of 23.7 months (SD ± 22.3). Surgical revisions occurred in 14/58 (24%) patients and 15/58 (26%) patients had the device explanted after a mean of 2.8 years (SD ± 1.7). Patients with greater than ten incontinence episodes per day were more likely to have a successful stage I trial compared to those with less than five (OR = 10.3; 95% CI 2.1 to 50.60).

Conclusions

Although SNS is a safe and effective therapy for lower urinary tract disorders, it is associated with a high reoperation rate.
Literatur
1.
Zurück zum Zitat Steers WD, Herschorn S, Kreder KJ et al (2007) Duloxetine OAB Study Group. Duloxetine compared with placebo for treating women with symptoms of overactive bladder. BJU Int 100(2):337–45PubMedCrossRef Steers WD, Herschorn S, Kreder KJ et al (2007) Duloxetine OAB Study Group. Duloxetine compared with placebo for treating women with symptoms of overactive bladder. BJU Int 100(2):337–45PubMedCrossRef
2.
Zurück zum Zitat Hu T, Wagner TH, Bentkover JD et al (2003) Estimated economic costs of overactive bladder in the United States. Urology 61(6):1123–1128PubMedCrossRef Hu T, Wagner TH, Bentkover JD et al (2003) Estimated economic costs of overactive bladder in the United States. Urology 61(6):1123–1128PubMedCrossRef
3.
Zurück zum Zitat Abrams P, Freeman R, Anderstrom C, Mattiason A (1998) Tolterodine, a new antimuscarinic agent: as effective but better tolerated than oxybutynin in patients with an overactive bladder. Br J Urol 81:801–810PubMedCrossRef Abrams P, Freeman R, Anderstrom C, Mattiason A (1998) Tolterodine, a new antimuscarinic agent: as effective but better tolerated than oxybutynin in patients with an overactive bladder. Br J Urol 81:801–810PubMedCrossRef
4.
Zurück zum Zitat Tanagho EA, Schmidt RA (1988) Electrical stimulation in the clinical management of the neurogenic bladder. J Urol 140:1331–9PubMed Tanagho EA, Schmidt RA (1988) Electrical stimulation in the clinical management of the neurogenic bladder. J Urol 140:1331–9PubMed
5.
Zurück zum Zitat Brazzelli M, Murray A, Fraser C (2006) Efficacy and safety of sacral nerve stimulation for urinary urge incontinence: a systematic review. J Urol 175(3):835–841PubMedCrossRef Brazzelli M, Murray A, Fraser C (2006) Efficacy and safety of sacral nerve stimulation for urinary urge incontinence: a systematic review. J Urol 175(3):835–841PubMedCrossRef
6.
Zurück zum Zitat Aboseif S, Tamaddon K, Chalfin S, Freedman S, Kaptein J (2002) Sacral neuromodulation as an effective treatment for refractory pelvic floor dysfunction. Urology 60(1):52–56PubMedCrossRef Aboseif S, Tamaddon K, Chalfin S, Freedman S, Kaptein J (2002) Sacral neuromodulation as an effective treatment for refractory pelvic floor dysfunction. Urology 60(1):52–56PubMedCrossRef
7.
Zurück zum Zitat Amundsen C, Romero AA, Jaminson MG, Webster GD (2005) Sacral neuromodulation for intractable urge incontinence: are there factors associated with a cure? Urology 66:746–750PubMedCrossRef Amundsen C, Romero AA, Jaminson MG, Webster GD (2005) Sacral neuromodulation for intractable urge incontinence: are there factors associated with a cure? Urology 66:746–750PubMedCrossRef
8.
Zurück zum Zitat Wallace PA, Lane FL, Noblett KL (2007) Sacral nerve neuromodulation in patients with underlying neurologic disease. Am J Obstet Gynecol 197(1):96.e1-1–96.e1-5 Wallace PA, Lane FL, Noblett KL (2007) Sacral nerve neuromodulation in patients with underlying neurologic disease. Am J Obstet Gynecol 197(1):96.e1-1–96.e1-5
9.
Zurück zum Zitat Uebersax JS, Wyman JF, Shumaker SA et al (1995) Short forms to assess life quality and symptom distress for urinary incontinence in women: the Incontinence Impact Questionnaire and the Urogenital Distress Inventory. Continence Program for Women Research Group. Neurourol Urodyn 14:131–9PubMedCrossRef Uebersax JS, Wyman JF, Shumaker SA et al (1995) Short forms to assess life quality and symptom distress for urinary incontinence in women: the Incontinence Impact Questionnaire and the Urogenital Distress Inventory. Continence Program for Women Research Group. Neurourol Urodyn 14:131–9PubMedCrossRef
10.
Zurück zum Zitat Schmidt RA, Jonas U, Oleson KA et al (1999) Sacral nerve stimulation for treatment of refractory urinary urge incontinence. J Urol 162:352PubMedCrossRef Schmidt RA, Jonas U, Oleson KA et al (1999) Sacral nerve stimulation for treatment of refractory urinary urge incontinence. J Urol 162:352PubMedCrossRef
11.
Zurück zum Zitat Bump RC, Mattiasson A, Bo K et al (1996) The standardization of terminology of female pelvic organ prolapse and pelvic floor dysfunction. Am J Obstet Gynecol 175:10–17PubMedCrossRef Bump RC, Mattiasson A, Bo K et al (1996) The standardization of terminology of female pelvic organ prolapse and pelvic floor dysfunction. Am J Obstet Gynecol 175:10–17PubMedCrossRef
12.
Zurück zum Zitat Haylen BT, de Ridder D, Freeman RM et al (2010) An international urogynecologic association (IUGA/ICS) joint report on the terminology for female pelvic floor dysfunction. Neurourolog Urodyn 29(1):4–20 Haylen BT, de Ridder D, Freeman RM et al (2010) An international urogynecologic association (IUGA/ICS) joint report on the terminology for female pelvic floor dysfunction. Neurourolog Urodyn 29(1):4–20
13.
Zurück zum Zitat Kessler T, Framboise DL, Trelle S et al (2010) Sacral neuromodulation for neurogenic lower urinary tract dysfunction: systemic review and meta-analysis. Eur Urol 58(6):865–74PubMedCrossRef Kessler T, Framboise DL, Trelle S et al (2010) Sacral neuromodulation for neurogenic lower urinary tract dysfunction: systemic review and meta-analysis. Eur Urol 58(6):865–74PubMedCrossRef
14.
Zurück zum Zitat Goh M, Diokno AC (2007) Sacral neuromodulation for nonobsrtuctive urinary retention—is success predictable? J Urology 178:197–19913CrossRef Goh M, Diokno AC (2007) Sacral neuromodulation for nonobsrtuctive urinary retention—is success predictable? J Urology 178:197–19913CrossRef
15.
Zurück zum Zitat Scheepens WA, Jongen GJ, Neiman FHM et al (2002) Predictive factors for sacral neuromodulation in chronic lower urinary tract dysfunction. Urology 60(4):598–602PubMedCrossRef Scheepens WA, Jongen GJ, Neiman FHM et al (2002) Predictive factors for sacral neuromodulation in chronic lower urinary tract dysfunction. Urology 60(4):598–602PubMedCrossRef
16.
Zurück zum Zitat Shumaker SA, Wyman JF, Uebersax JS et al (1994) Health-related quality of life measures for women with urinary incontinence: the Incontinence Impact Questionnaire and the Urogenital Distress Inventory. Continence Program in Women (CPW) Research Group. Qual Life Res 3:291–306PubMedCrossRef Shumaker SA, Wyman JF, Uebersax JS et al (1994) Health-related quality of life measures for women with urinary incontinence: the Incontinence Impact Questionnaire and the Urogenital Distress Inventory. Continence Program in Women (CPW) Research Group. Qual Life Res 3:291–306PubMedCrossRef
17.
Zurück zum Zitat Siegel SW, Catanzaro F, Dijkema HE, Elhilali MM, Fowler CJ, Gajewski JB et al (2000) Long-term results of a multicenter study on sacral nerve stimulation for treatment of urinary urge incontinence, urgency-frequency, and retention. Urology 56(6):87–91, suppl.1PubMedCrossRef Siegel SW, Catanzaro F, Dijkema HE, Elhilali MM, Fowler CJ, Gajewski JB et al (2000) Long-term results of a multicenter study on sacral nerve stimulation for treatment of urinary urge incontinence, urgency-frequency, and retention. Urology 56(6):87–91, suppl.1PubMedCrossRef
18.
Zurück zum Zitat Bosch JL (2010) An update on sacral neuromodulation: where do we stand with this in the management of lower tract dysfunction in 2010? BJU 106(10):1432–42CrossRef Bosch JL (2010) An update on sacral neuromodulation: where do we stand with this in the management of lower tract dysfunction in 2010? BJU 106(10):1432–42CrossRef
19.
Zurück zum Zitat Hijaz A, Sandip VP, Daneshgari F, Frinjari H, Goldman H, Rackley R (2006) Complications and troubleshooting of two-staged sacral neuromodulation therapy: a single institutions experience. Urology 68(3):533–537PubMedCrossRef Hijaz A, Sandip VP, Daneshgari F, Frinjari H, Goldman H, Rackley R (2006) Complications and troubleshooting of two-staged sacral neuromodulation therapy: a single institutions experience. Urology 68(3):533–537PubMedCrossRef
20.
Zurück zum Zitat White WM, Mobley JD, Doggweiler R, Dobmeyer-Dittrich C, Klein FA (2009). Incidence and predictors of complications with sacral neuromodulation. 73(4);731-35 White WM, Mobley JD, Doggweiler R, Dobmeyer-Dittrich C, Klein FA (2009). Incidence and predictors of complications with sacral neuromodulation. 73(4);731-35
Metadaten
Titel
Determining outcomes, adverse events, and predictors of success after sacral neuromodulation for lower urinary disorders in women
verfasst von
Tajnoos Yazdany
Narender Bhatia
John Nguyen
Publikationsdatum
01.12.2011
Verlag
Springer-Verlag
Erschienen in
International Urogynecology Journal / Ausgabe 12/2011
Print ISSN: 0937-3462
Elektronische ISSN: 1433-3023
DOI
https://doi.org/10.1007/s00192-011-1512-2

Weitere Artikel der Ausgabe 12/2011

International Urogynecology Journal 12/2011 Zur Ausgabe

Nodal-negativ nach neoadjuvanter Chemo: Axilladissektion verzichtbar?

03.05.2024 Mammakarzinom Nachrichten

Wenn bei Mammakarzinomen durch eine neoadjuvante Chemotherapie ein Downstaging von nodal-positiv zu nodal-negativ gelingt, scheint es auch ohne Axilladissektion nur selten zu axillären Rezidiven zu kommen.

Rezidivierender Peritonsillarabszess nach Oralsex

02.05.2024 Peritonsillarabszess Kasuistik

Die erotischen Dimensionen von Peritonsillarabszessen scheinen eng begrenzt zu sein. Das heißt aber nicht, solche Abszesse und Erotik hätten nichts miteinander gemein, wie ein Fallbericht verdeutlicht.

Endlich: Zi zeigt, mit welchen PVS Praxen zufrieden sind

IT für Ärzte Nachrichten

Darauf haben viele Praxen gewartet: Das Zi hat eine Liste von Praxisverwaltungssystemen veröffentlicht, die von Nutzern positiv bewertet werden. Eine gute Grundlage für wechselwillige Ärzte und Psychotherapeuten.

Ambulantisierung: Erste Erfahrungen mit dem Hybrid-DRG

02.05.2024 DCK 2024 Kongressbericht

Die Hybrid-DRG-Verordnung soll dazu führen, dass mehr chirurgische Eingriffe ambulant durchgeführt werden, wie es in anderen Ländern schon länger üblich ist. Die gleiche Vergütung im ambulanten und stationären Sektor hatten Niedergelassene schon lange gefordert. Aber die Umsetzung bereitet ihnen doch Kopfzerbrechen.

Update Gynäkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.